0000950116-01-501010.txt : 20011030
0000950116-01-501010.hdr.sgml : 20011030
ACCESSION NUMBER: 0000950116-01-501010
CONFORMED SUBMISSION TYPE: SC 13D/A
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20011026
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: INPHARZAM INTERNATIONAL S A
CENTRAL INDEX KEY: 0001064797
STANDARD INDUSTRIAL CLASSIFICATION: []
FILING VALUES:
FORM TYPE: SC 13D/A
BUSINESS ADDRESS:
STREET 1: VIA INDUSTRIA I
CITY: CADEMPINO
STATE: V8
ZIP: 00000
BUSINESS PHONE: 2018962200
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000894158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133808303
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13D/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-50777
FILM NUMBER: 1766973
BUSINESS ADDRESS:
STREET 1: 425 WOODSMILL RD
CITY: ST LOUIS
STATE: MO
ZIP: 63017
BUSINESS PHONE: 3145799899
MAIL ADDRESS:
STREET 1: 425 WOODSMILL RD
CITY: ST LOUIS
STATE: MO
ZIP: 63017
FORMER COMPANY:
FORMER CONFORMED NAME: SHEFFIELD MEDICAL TECHNOLOGIES INC
DATE OF NAME CHANGE: 19940606
SC 13D/A
1
sc13d-a.txt
SC 13D/A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
SHEFFIELD PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $.01 Per Share
--------------------------------------------------------------------------------
(Title of Class of Securities)
821230309
--------------------------------------------------------------------------------
(CUSIP Number)
Spencer W. Franck, Jr.
Saul Ewing LLP
1200 Liberty Ridge Drive, Suite 200
Wayne, PA 19087
610-251-5082
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and Communications)
October 19, 2001
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[_]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 821230309
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (entities only)
Inpharzam International, S.A.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. SOURCE OF FUNDS
SC
--------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(D) OR 2(E) [ ]
--------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
--------------------------------------------------------------------------------
Number of Shares Beneficially 7. Sole Voting Power
Owned By Each Reporting Person With 0
8. Shared Voting Power
0
9. Sole Dispositive Power
2,431,156
10. Shared Dispositive Power
0
--------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,431,156
--------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) [ ]
--------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
8.37%
--------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
------------------------------------------------------------------------------
This Amendment No. 2 to Schedule 13D relates to a Schedule 13D filed with
the Securities and Exchange Commission ("SEC") on June 26, 1998, as amended by
Amendment No. 1 to Schedule 13D, filed with the SEC on October 4, 2001
(collectively, the "Schedule 13D"). Information contained in the Schedule 13D
remains in effect except to the extent that it is superseded by the information
contained in this Amendment No. 2. Information given in response to each item
shall be deemed to be incorporated by reference in all other items. Capitalized
terms used but not defined in this Amendment No. 2 shall have the meanings
ascribed to such terms in the Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 is hereby amended in its entirety to read as follows:
On June 15, 1998, Inpharzam spent $2,150,000 from its working capital to
purchase 2,646,153 Shares.
On September 28, 2001, in connection with an Amendment to Sublicense and
Development Agreement (the "Sublicense Amendment") by and between the Issuer and
Inpharzam, the Issuer repurchased 214,997 Shares from Inpharzam for a total
purchase price of $642,841.03. Such purchase price was paid from the Issuer's
working capital. Such repurchase was in partial consideration of Inpharzam's
assignment of certain intellectual property to the Issuer pursuant to the terms
of the Sublicense Amendment. The Sublicense Amendment was filed as Exhibit 1 to
Amendment No. 1 to Schedule 13D.
Item 4. Purpose of Transaction
Item 4 is hereby amended in its entirety to read as follows:
All of the Shares to which this statement relates were acquired for
investment purposes only.
Inpharzam intends to review on a continuing basis its investment in the
Shares of the Issuer and may in the future purchase additional Shares or dispose
of Shares now held. Pursuant to the Sublicense Amendment, Inpharzam granted the
Issuer an option, expiring on December 31, 2002, to reacquire the remaining
2,431,156 Shares held by Inpharzam for $3.03 per Share. In addition, Inpharzam
agreed to sell to the Issuer, and the Issuer agreed to purchase, up to 1,549,105
Shares at a purchase price of $3.03 per Share in the event the Issuer completes
a sublicense for certain intellectual property, as described in the Sublicense
Amendment, with one or more third parties prior to December 31, 2002.
On October 11, 2001, effective as of September 28, 2001 and pursuant to
Section 4(b) of the Sublicense Amendment, Roberto Rettani, Vice President of
Inpharzam, resigned his position as a member of the Issuer's board of directors.
Except as set forth herein or in the Schedule 13D, Inpharzam does not
presently have plans or proposals which relate to or would result in (a) the
acquisition by any person of additional securities of the Issuer, (b) an
extraordinary corporate transaction, such as a merger, reorganization or
liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or
transfer of a material amount of assets of the Issuer or any of its
subsidiaries; (d) any change in the present board of directors or management of
the Issuer, including any plans or proposals to change the number or term of
directors or to fill any existing vacancies on the board; (e) any material
change in the present capitalization or dividend policy of the Issuer; (f) any
other material change in the Issuer's business or corporate structure; (g)
changes in the Issuer's Certificate of Incorporation or By-Laws or other actions
which may impede the acquisition of control of the Issuer by any person; (h)
causing a class of securities of the Issuer to be delisted from a national
securities exchange or to cease to be authorized to be quoted in an inter-dealer
quotation system of a registered national securities association; (i) a class of
equity securities of the Issuer becoming eligible for termination of
registration pursuant to Section 12(g)(4) of the Securities Exchange Act of
1934, as amended; or (j) any action similar to any of those enumerated above.
Item 5. Interest in the Securities of the Issuer
Item 5 is hereby amended in its entirety to read as follows:
(a) After giving effect to the transactions described below, Inpharzam
beneficially owned 2,431,156 Shares, all of which it held directly, representing
8.37% of the Issuer's outstanding Shares.
(b) On October 19, 2001, Inpharzam executed and delivered to the Issuer an
Irrevocable Proxy (the "Proxy"), appointing the Chairman of the Board of Issuer,
Thomas M. Fitzgerald, as Inpharzam's attorney-in-fact and proxy to attend any
and all meetings of Issuer's stockholders and to vote all shares of Issuer's
common stock currently held by Inpharzam. A copy of the Proxy is attached hereto
as Exhibit 1. The Proxy is effective as of September 28, 2001 and shall remain
in effect until December 31, 2002, unless earlier terminated in accordance with
its terms. The Proxy may be terminated by Inpharzam in the event that the Issuer
shall be in breach of its obligations under the Sublicense Amendment or the Loan
and Security Agreement, dated as of September 28, 2001, by and between Inpharzam
and the Issuer, and such breach shall not have been cured within 15 days of
written notice of such breach from Inpharzam to the Issuer. Inpharzam retains
the sole power to dispose of all such Shares.
(c) Not applicable.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to
Securities of the Issuer
Item 6 is hereby amended to include the following:
On or about October 15, 2001, Inpharzam executed and delivered to the
Issuer the Proxy, filed as Exhibit 1 hereto, and the terms of which are
incorporated herein by reference, pursuant to which Inpharzam appointed the
Chairman of the Board of Issuer, Thomas M. Fitzgerald, as Inpharzam's
attorney-in-fact and proxy to attend any and all meetings of Issuer's
stockholders and to vote all shares of Issuer's common stock currently held by
Inpharzam, as described above.
Item 7. Material to be Filed as Exhibits
Item 7 is hereby amended to include the following:
The following documents are filed as exhibits to this Amendment No. 2:
1. Irrevocable Proxy, dated as of September 28, 2001
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, we
certify that the information set forth in this statement is true, complete and
correct.
INPHARZAM INTERNATIONAL, S.A.
By: /s/ Alberto Zambon
---------------------------------
Name: Alberto Zambon
---------------------------------
Title: President
---------------------------------
EXHIBIT INDEX
Exhibit 1 Irrevocable Proxy, dated as of September 28, 2001, executed and
delivered by Inpharzam International, S.A., in favor of the Chairman
of the Board of Sheffield Pharmaceuticals, Inc., Thomas M.
Fitzgerald
EX-1
3
ex-1.txt
EX-1
EXHIBIT 1
Impharzam International
IRREVOCABLE PROXY
The undersigned, INPHARZAM INTERNATIONAL, S.A. ("Holder"), with a
principal office located at Via Industria 1, 7814 Cadempino, Switzerland, hereby
revokes any and all proxies heretofore granted with respect to any shares of
common stock, $.01 par value, of Sheffield Pharmaceuticals, Inc., a Delaware
corporation ("Sheffield"), now held by Holder (the "Holder Stock"), and hereby
irrevocably appoints the Chairman of the Board of Sheffield, Thomas M.
Fitzgerald, as attorney-in-fact and proxy of Holder to attend any and all
meetings of the stockholders of Sheffield and to vote the Holder Stock, to
represent and otherwise to act for Holder in the same manner and with the same
effect as if such Holder were personally present at such meetings with respect
to the Holder Stock and to act by consent with respect to the Holder Stock in
the same manner and with the same effect as if Holder were executing such
consent, with respect to any matter.
Holder agrees that, so long as this Irrevocable Proxy remains in
effect, Holder will not execute or deliver to any persons, any proxy forms with
respect to the Holder Stock relating to any meeting, or written consent in lieu
of a meeting, of stockholders of Sheffield and will not take any action
inconsistent with this Irrevocable Proxy.
The foregoing appointment shall be (a) absolute and irrevocable and (b)
deemed coupled with an interest in that Sheffield has obtained an option to
purchase all shares of Holder Stock pursuant to that certain Amendment to
Sublicense and Development Agreement, dated of even date herewith, by and
between Holder and Sheffield (the "Amendment").
This Irrevocable Proxy shall be effective until December 31, 2002, in
accordance with Delaware law, unless earlier terminated as hereinafter provided,
and may be relied upon by any third party.
This Irrevocable Proxy may be terminated by Holder in the event that
Sheffield shall be in breach of its obligations under the Sublicense and
Development Agreement, dated June 15, 1998, between Holder and Sheffield, as
amended by the Amendment, or the Loan and Security Agreement, dated as of
September 28, 2001, and such breach shall not have been cured within 15 days of
written notice of such breach from Holder to Sheffield.
IN WITNESS WHEREOF, the undersigned Holder has executed this
Irrevocable Proxy as of September 28, 2001.
Witness:
INPHARZAM INTERNATIONAL, S.A.
/s/ Alberto Zambon
--------------------------------------------
Name: Dr. Alberto Zambon
Title: President